Year-end Sale % OFF 
Abstract
‘DARAPRIM’ [2 : 4-diamino-5-(-4′-chlorophenyl)-6-ethyl pyrimidine (50–63) ] has been described1 as having high antimalarial activity in laboratory infections of Plasmodium gallinaceum, Plasmodium berghei and Plasmodium cynomolgi. More recently, it has also been tried in the treatment and suppression of human malaria2. It has been shown that proguanil-resistant strains of the first two species are sensitive to ‘Daraprim’ and that ‘Daraprim’ resistance is not easily produced in P. gallinaceum infections3.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
